NEW YORK, Dec.

Inotek announced today that the Company has focused its resources on the development of its two main clinical programs and the advancement of its two preclinical programs, including the partnering of its monoclonal antibody program.

Inotek Pharmaceuticals Corporation announced today that it has closed a Series C financing, raising $19.3 million.

Inotek Pharmaceuticals Corporation announced today the publication in the journal Stroke of preclinical animal data showing that the administration of a poly(ADP-Ribose) polymerase (PARP) inhibitor has a large protective effect on the survival of certain brain cells following a stroke.

Genentech is to pay Inotek Pharmaceuticals up to $405 million in a collaboration to discover, develop, manufacture and commercialize new drugs for the treatment of cancer. The collaboration will focus on inhibitors of poly (ADP-ribose) polymerase (PARP).